RT Journal Article SR Electronic T1 Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 795 OP 805 DO 10.21873/anticanres.14011 VO 40 IS 2 A1 POLINA E. KISARETOVA A1 SVETLANA S. KIRIKOVICH A1 GENRICH S. RITTER A1 YAROSLAV R. EFREMOV A1 OLEG S. TARANOV A1 TATYANA D. DUBATOLOVA A1 ANASTASIA S. PROSKURINA A1 EKATERINA A. POTTER A1 EVGENIA V. DOLGOVA A1 SERGEY V. SIDOROV A1 ALEKSANDR A. OSTANIN A1 ELENA R. CHERNYCH A1 SERGEY S. BOGACHEV YR 2020 UL http://ar.iiarjournals.org/content/40/2/795.abstract AB Background/Aim: We previously have described the “3+1” tumors cure approach consisting of individual time schedule of cyclophosphamide and dsDNA preparation administrations. The aim of the study was to adapt the “3+1” approach based on eradication of cancer stem cells to the model of murine ascitic cyclophosphamide-resistant lymphosarcoma (RLS). Materials and Methods: Adaptation of the “3+1” approach includes the identification of the timing to disrupt the tumorigenic potential of a certain tumor. Results: The proposed therapeutic scheme allowed complete reduction of primary RLS ascites in experimental animals. However, reduction of primary ascites due to the complementary action of cyclophosphamide and dsDNA was inevitably followed by the development of a secondary one, most likely arising from a solid carcinomatous formation in the peritoneal wall. Conclusion: The “3+1” approach resulted in the elimination of cancer stem cells, and, as a consequence, in the complete reduction of RLS ascites.